OPPORTUNITIES
Forecasts predict that by 2016 Pakistan will be the 11th largest pharmaceutical market in the Asia Pacific region, which is the major core world’s population and growth pole.
The industry is a net beneficiary of the boom in base materials mostly from China and this positively impacts their margins. Further treaties and trade agreements will boost this trend further.
The country’s Large Scale Manufacturing (LSM) has registered positive growth of 1.85 percent during the July-Sep first quarter of the current FY13 over the corresponding period of the last FY12 showing signs of improvements. The manufacturing items observed growth throughout the first quarter over the same period of last year involved pharmaceuticals (4.09%).
FBR has reduced the rate of the 0.5 percent withholding tax under Section 153A of the Income Tax Ordinance, 2001 to 0.3 or 0.2 percent for those segments reimbursing lower rate of turnover tax below 0.5 percent. This has yearned to be a major facilitative measure to be announced for all such sectors like manufacturers of pharmaceutical products having low turnover and also paying turnover taxes that are high. By volumes and generated percentage, the Pharmaceutical industry might possibly be considered a small industry which can prove itself of substantial value considering the amount of profits that can be generated, and the number of promising investors that exist. Enormous prospective exists for the Industry in a country of
Economic: Globalization of the pharmaceutical industry is an exciting opportunity to have research and development done at cheaper prices in other countries. However, this could be a double edged sword for companies because it is easy for other countries, such as India, to produce generic versions of the drug in bulk.
U.S. based companies hold rights to most of the world’s rights on new medicines and holds thousands of new products currently being developed. As of 2012, the industry helps support almost 3.4 million jobs in the U.S. economy. It is also one of the most heavily R&D based industries in the world. In the United States, the environment for pharmaceuticals is much friendlier than other countries around the world in terms of pricing ability and regulations. Both the Pharmaceutical and Biotechnology industries have experienced significant growth in the past year with year-over-year increases of 13.02% and 34.69% respectively. It is an even more striking when looking at the past five years considering both have beat out the S&P 500 with pharmaceuticals increasing an additional 31.44% and the biotechnology sector besting an astonishing 269.3% more return than the
prescription drugs, which will play a big role in the increase of profits for pharmaceutical
Choosing one aspect of paper and focusing on all products and competitors so the material is available when the time comes to write the paper
The pharmaceutical industry continues to be a major driver of trend. While demand for medicine rapidly increases in emerging economies, a growing number of consumers are also analyzing the economic performance of different medicines. These events will heighten the challenges the
There are advantages of starting a pharmaceutical firm in India. It has emerged from being an enzyme-producing firm to a biotech powerhouse under the guidance of Ms Kiran M. Shaw. They have a well-established pharmaceutical industry that has been growing since 1947. After the purchase of Hindustan Antibiotics Ltd. and India Drug and Pharmaceuticals Ltd. they were able to compete with the MNC’s (Multi National Corporaton) from overseas (Kalegaonkar, Locke, Lehrich, 2008, p. 2). In the beginning the pharmaceutical industry saw substantial growth. “By the beginning of the 21st century, over 20,000 pharmaceutical companies were operating in India” (Kalegaonkar, Locke, Lehrich, 2008, p. 2). “The pharmaceutical industry in India is ranked third
Besides that, the pharmaceuticals are extremely global; it is worth approximately $300 billion a years and expected to increase to $400 billion around the next three years
PharmaCARE will not face any liability over its practices under current federal and state laws. Federal laws are vague and under reaching and in the case of CompCARE, the facility will not be classified as a drug manufacturer, which eliminates almost entirely the possibilities of regulation by current federal laws. The FDA does not consider compounded drugs to be as safe as those manufactured in large plants that have to meet standards for quality assurance and urges consumers to use FDA approved drugs. All though the FDA knows the risk of traditionally compounded drugs, the FDA doesn't know just how many compounding pharmacies exist in the United States. Also, states that do much of the regulation for compounding pharmacies are not themselves
We analyzed the Indian Pharmaceutical industry on these five forces and the findings of industry competitiveness and profitability are written under the relevant competitive forces.
Pharmaceutical Sciences is a topic that has interested me for a while now. What I can say about this topic is that it will help humanity grow as a whole and keep everyone moving forward. This is a topic where people really need to think about what goes behind the scenes of your average pharmacies. Once people start to think about it, they would start to realize that the science that happens is extremely crucial to mankind as we know it. Without this kind of science, where would humans be today? Would we have the ability to evolve the way we have? How far would humans make it to creating today’s future as we know it? The simple answer to all these questions is
Drug portfolio management is one of the most important determinants of long-term prosperity of research-oriented pharmaceutical companies.
Further more, with other benefits such as low costs in research and development, strong clinical research capabilities, and low sovereign risk, Australia is advancing as one of the most prominent players in the pharmaceutical industry (Productivity Commission 2003). Australia’s population represents 0.3% of the world’s population and consumes around 1% of the total global pharmaceutical sales. The industry generated a total revenue of $6.1 billion in the year 2002 (ALRC 2014).
This report provides an analytical strategic review of the global pharmaceutical industry; its origin, evolution,
Although R&D has been retained by the large pharmaceutical firms, there has been a continuous decline in the R&D productivity. Controlling R&D is imperative to the success of a Pharmaceutical firm. However, as the pharmaceutical industry is maturing, there are diminishing returns to the R&D investment. Fewer and fewer blockbuster drugs are being discovered and therefore R&D is not the most value adding component in the value
ISSN: 2277- 7695 TPI 2014; 3(7): 08-12 © 2013 TPI www.thepharmajournal.com Received: 14-08-2014 Accepted: 28-08-2014 Rizwan Raheem Ahmed Professor, Department of Business Administration & Commerce Indus University, Pakistan